These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22907940)

  • 21. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
    Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C
    Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis.
    Jilek S; Schluep M; Rossetti AO; Guignard L; Le Goff G; Pantaleo G; Du Pasquier RA
    Clin Immunol; 2007 Apr; 123(1):105-13. PubMed ID: 17188575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing remitting multiple sclerosis patient.
    Govarts C; Somers K; Hupperts R; Stinissen P; Somers V
    Autoimmunity; 2009; 42(8):699-704. PubMed ID: 19835487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A subtype of multiple sclerosis defined by an activated immune defense program.
    van Baarsen LG; van der Pouw Kraan TC; Kragt JJ; Baggen JM; Rustenburg F; Hooper T; Meilof JF; Fero MJ; Dijkstra CD; Polman CH; Verweij CL
    Genes Immun; 2006 Sep; 7(6):522-31. PubMed ID: 16837931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
    Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
    FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brief presence of varicella-zoster vral DNA in mononuclear cells during relapses of multiple sclerosis.
    Ordoñez G; Pineda B; Garcia-Navarrete R; Sotelo J
    Arch Neurol; 2004 Apr; 61(4):529-32. PubMed ID: 15096401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FADD is upregulated in relapsing remitting multiple sclerosis.
    Reuss R; Mistarz M; Mirau A; Kraus J; Bödeker RH; Oschmann P
    Neuroimmunomodulation; 2014; 21(5):221-5. PubMed ID: 24603611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus.
    Mandel M; Gurevich M; Pauzner R; Kaminski N; Achiron A
    Clin Exp Immunol; 2004 Oct; 138(1):164-70. PubMed ID: 15373920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid concentrations of ghrelin in patients with multiple sclerosis.
    Unger MM; Oertel WH; Tackenberg B
    Neuro Endocrinol Lett; 2013; 34(1):14-7. PubMed ID: 23524619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.
    Thangarajh M; Gomez-Rial J; Hedström AK; Hillert J; Alvarez-Cermeño JC; Masterman T; Villar LM
    Mult Scler; 2008 Nov; 14(9):1208-13. PubMed ID: 18755821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
    Martínez-Yélamos A; Saiz A; Bas J; Hernandez JJ; Graus F; Arbizu T
    Neurosci Lett; 2004 Jun; 363(1):14-7. PubMed ID: 15157986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase of CD4+TNF{alpha}+IL-2-T cells in cerebrospinal fluid of multiple sclerosis patients.
    Shi N; Kawano Y; Matsuoka T; Mei F; Ishizu T; Ohyagi Y; Kira J
    Mult Scler; 2009 Jan; 15(1):120-3. PubMed ID: 18755820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.
    Lindberg RL; Hoffmann F; Mehling M; Kuhle J; Kappos L
    Eur J Immunol; 2010 Mar; 40(3):888-98. PubMed ID: 20148420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Dobosz B; Stelmasiak Z
    Acta Neurol Scand; 2004 Jun; 109(6):390-2. PubMed ID: 15147461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.
    Szczuciński A; Losy J
    Neuroimmunomodulation; 2011; 18(1):67-72. PubMed ID: 20720435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of CD24 and its expression in Iranian relapsing-remitting multiple sclerosis.
    Kollaee A; Ghaffarpor M; Pourmahmoudian H; Shahbazi M; Zamani M
    Int J Neurosci; 2011 Dec; 121(12):684-90. PubMed ID: 21815873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: Equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome.
    Johansen JN; Vartdal F; Desmarais C; Tutturen AE; de Souza GA; Lossius A; Holmøy T
    Clin Immunol; 2015 Oct; 160(2):211-25. PubMed ID: 26055752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.